Trial Profile
A Retrospective Study Investigating the Safety and Efficacy of Ruxolitinib and Vitamin K Antagonists in the Treatment of Patients with Primary Myelofibrosis with IPSS INT-2
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary) ; Warfarin (Primary) ; Hydroxycarbamide
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 29 Jul 2018 New trial record
- 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association.